SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Mattson RH, Cramer JA, The choice of antiepileptic drugs in focal epilepsy. In: WyllieE, ed. The treatment of epilepsy. Principles and practice. 1st ed. Philadelphia : Lea & Febiger, 1993:81723.
  • 2
    International League Against Epilepsy Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia 1998;39:799803.
  • 3
    Ferrendelli JA, Relating pharmacology to clinical practice: the pharmacologic basis of rational polypharmacy. Neurology 1995;45(Suppl. 2):126.
  • 4
    Hakkarainen H., Carbamazepine vs. diphenylhydantoin vs. their combination in adult epilepsy. Neurology 1980;30:354.
  • 5
    Goldsmith P, de Bittencourt PRM, Rationalized polytherapy for epilepsy. Acta Neurol Scand 1995;(Suppl. 162):359.
  • 6
    Klitgaard H, Knudsen ML, Jackson HC, Synergism between drugs with different mechanisms of action against audiogenic seizures in DBA/2 mice. Epilepsia 1993;34(Suppl. 6):934.
  • 7
    Dichter MA, Basic mechanisms of epilepsy: targets for therapeutic intervention. Epilepsia 1997;38(Suppl. 9):S26.
  • 8
    Snead OC, Basic mechanisms of generalized absence seizures. Ann Neurol 1995;37:14657.
  • 9
    Meldrum BS, Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996;37(Suppl. 6):411.
  • 10
    Macdonald RL, Is there a mechanistic basis for rational polypharmacy? In: HomanRW, LeppikIE, LothmanEW, PenryJK, TheodoreWH, eds. Rational polypharmacy. Amsterdam : Elsevier Science BV, 1996:7993.
  • 11
    Löscher W., Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Progr Neurobiol 1999;58:3159.
  • 12
    White HS, Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;40(Suppl. 5):210.
  • 13
    Gale K., GABA and epilepsy: basic concepts from preclinical research. Epilepsia 1992;33(Suppl. 5):312.
  • 14
    Besag FMC, Wallace SJ, Dulac O, Alving J, Spencer SC, Hosking G., Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:9917.
  • 15
    Löscher W., Animal models of intractable epilepsy. Progr Neurobiol 1997;53:23958.
  • 16
    Schwarz JR, Grigat G., Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 1989;30:28694.
  • 17
    Prichard JW, Ransom BR, Phenobarbital: mechanisms of action. In: LevyRH, MattsonRH, MeldrumBS, eds. Antiepileptic drugs. 4th ed. New York : Raven Press, 1995:35969.
  • 18
    Weaver LC, Swinyard EA, Woodbury LA, Goodman LS, Studies on anticonvulsant drug combinations: phenobarbital and diphenylhydantoin. J Pharmacol Exp Ther 1955;113:35970.
  • 19
    Leppik IE, Sherwin AL, Anticonvulsant activity of phenobarbital and phenytoin in combination. J Pharmacol Exp Ther 1977;200:5705.
  • 20
    Masuda Y, Utsui Y, Shiraishi Y, Karasawa T, Yoshida K, Shimizu M., Evidence for a synergistic interaction between phenytoin and phenobarbital in experimental animals. J Pharmacol Exp Ther 1981;217:80511.
  • 21
    Picker M, Thomas J, Koch C, Poling A., Effects of phenytoin, phenobarbital and valproic acid, alone and in selected combinations, on schedule-controlled behavior of rats. Pharmacol Biochem Behav 1985;22:38993.
  • 22
    Bourgeois BFD, Dodson WE, Antiepileptic and neurotoxic interactions between antiepileptic drugs. In: PitlickWH, ed. Antiepileptic drug interactions. New York : Demos, 1989:20918.
  • 23
    Stringer JL, Higgins MG, Interaction of phenobarbital and phenytoin in an experimental model of seizures in rats. Epilepsia 1994;35:21620.
  • 24
    Schmutz M, Baltzer V, Koella WP, Combination of carbamazepine and valproate sodium in mice, rats and cats. 11th Epilepsy International Symposium, Florence , 1979; Abstracts 148.
  • 25
    Morris JC, Dodson WE, Hatlelid JM, Ferrendelli JA, Phenytoin and carbamazepine, alone and in combination: anticonvulsant and neurotoxic effects. Neurology 1987;37:11118.
  • 26
    Chez MG, Bourgeois BFD, Pippenger CE, Knowles WD, Pharmacodynamic interactions between phenytoin and valproate: individual and combined antiepileptic and neurotoxic actions in mice. Clin Neuropharmacol 1994;17:327.
  • 27
    Della Paschoa OE, Kruk MR, Hamstra R, Voskuyl RA, Danhof M., Pharmacodynamic interaction between phenytoin and sodium valproate changes seizure thresholds and pattern. Br J Pharmacol 1998;125:9971004.
  • 28
    Czuczwar SJ, Turski L, Kleinrok Z., Effects of combined treatment with diphenylhydantoin and different benzodiazepines on pentylenetetrazol- and bicuculline-induced seizures in mice. Neuropharmacology 1982;21:5637.
  • 29
    Czuczwar SJ, Chmielewska B, Kozicka M, Kleinrok Z., Effect of combined treatment of diphenylhydantoin with clonazepam and chlordiazepoxide on the threshold for maximal electroconvulsions in mice. Methods Find Exp Clin Pharmacol 1983;5:337.
  • 30
    Musolino R, Gallito G, De Domenico P, et al. Synergistic anticonvulsant effect of valproic acid and ethosuximide on pentylenetetrazole-induced epileptic phenomena in rats. J Int Med Res 1991;19:5562.
  • 31
    Roks G, Deckers CLP, van Egmond J, Meinardi H, van Rijn CM, Effects of monotherapy and polytherapy with antiepileptic drugs: an animal study. J Pharmacol Exp Ther 1999;288:4727.
  • 32
    Bourgeois B, Van Lente F., Effect of clonazepam on antiepileptic potency, neurotoxicity and therapeutic index of valproate and ethosuximide in mice. Epilepsia 1994;35(Suppl. 8):142.
  • 33
    De Sarro G, Nava F, Aguglia U, De Sarro A., Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Neuropharmacology 1996;35:1538.
  • 34
    Stephen LJ, Sills GJ, Brodie MJ, Lamotrigine and topiramate may be a useful combination. Lancet 1998;351:9589.
  • 35
    De Sarro G, Spagnolo C, Gareri P, Galleli L, De Sarro A., Gahapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice. Eur J Pharmacol 1998;349:17985.
  • 36
    Gordon R, Gels M, Wichmann J, Diamantis W, Sofia RD, Interaction of felbamate with several other antiepileptic drugs against seizures induced by maximal electroshock in mice. Epilepsia 1993;34:36771.
  • 37
    Gordon R, Gels M, Diamantis M, Sofia RD, Interaction of felbamate and diazepam against maximal electroshock seizures and chemoconvulsants in mice. Pharmacol Biochem Behav 1991;40:10913.
  • 38
    Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994;35:45060.
  • 39
    Berenbaum MC, What is synergy Pharmacol Rev 1989;41:93141.
  • 40
    Tallarida RJ, Statistical analysis of drug combinations for synergism. Pain 1992;49:937.
  • 41
    Borowicz KK, Stasiuk G, Teter J, Kleinrok Z, Gasior M, Czuczwar SJ, Low propensity of conventional antiepileptic drugs for interaction with felbamate against maximal electroshock-induced seizures in mice. J Neural Transm 2000;107:73343.
  • 42
    Gennings C, Sofia RD, Carchman A, Carter WH Jr, Swinyard EA, Analysis of anticonvulsant and neurotoxic responses to combination therapy with carbamazepine, felbamate and phenytoin by response-surface modeling. Arzneimittelforschung/Drug Res 1995;45:73948.
  • 43
    Gruber CM Jr, Mosier JM, Grant P, Glen R., Objective comparison of phenobarbital and diphenylhydantoin in epileptic patients. Neurology 1956;6:6405.
  • 44
    Painter MJ, Scher M, Stein AD, et al. Phenobarbital with phenytoin for the treatment of neonatal seizures. N Engl J Med 1999;341:4859.
  • 45
    Cereghino JJ, Brock JT, Van Meter JC, Penry JK, Smith LD, White BG, The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther 1975;18:73341.
  • 46
    Brodie MJ, Yuen AWC, 105 Study Group. Lamotrigine substitution study: evidence for synergism with valproate Epilepsy Res 1997;26:42332.
  • 47
    Armour DJ, Veitch GB, Is valproate monotherapy a practical possibility in chronically uncontrolled epilepsy J Clin Pharm Ther 1988;13:5364.
  • 48
    Dean JC, Penry JK, Carbamazepine/valproate therapy in 100 patients with partial seizures failing carbamazepine monotherapy: long-term follow-up. Epilepsia 1988;29:687.
  • 49
    Fröscher W, Stoll KD, Hoffman F., Kombinationsbehandlung mit Carbamazepin und Valproinsaure bei Problemfallen einer Epilepsie-Ambulanz. Arzneimittelforschung/Drug Res 1983;34:9104.
  • 50
    Harden CL, Zisfein J, Atos-Radzion EC, Tuchmann AJ, Combination valproate-carbamazepine therapy in partial epilepsies resistant to carbamazepine monotherapy. J Epilepsy 1993;6:914.
  • 51
    Walker JE, Koon P., Carbamazepine versus valproate versus combined therapy for refractory partial complex seizures with secondary generalization. Epilepsia 1988;29:693.
  • 52
    Tatzer E, Groh C, Muller R, Lischka A., Carbamazepine and benzodiazepines in combination: a possibility to improve the efficacy of treatment of patients with “intractable” infantile spasms Brain Dev 1987;9:4157.
  • 53
    Hosada N, Miura H, Takanashi S, Shirai H, Sunaoshi W., The long-term effectiveness of clonazepam in the control of partial seizures in children difficult to control with carbamazepine monotherapy. Jpn J Psychiatry Neurol 1991;45:4713.
  • 54
    Murri L, Iudice A., Vigabatrin as first add-on treatment in carbamazepine-resistant patients. Acta Neurol Scand 1995;(Suppl. 162):402.
  • 55
    Tanganelli P, Regesta G., Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res 1996;25:25762.
  • 56
    Rowan AJ, Meijer JWA, de Beer-Pawlikowski N, van der Geest P, Meinardi H., Valproate-ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983;40:797802.
  • 57
    Mireles R, Leppik IE, Valproate and clonazepam comedication in patients with intractable epilepsy. Epilepsia 1985;26:1226.
  • 58
    Rosenberry KR, Korberly BH, Graziani LJ, Combination of clonazepam and sodium valproate in the treatment of refractory epileptic seizures. Am J Hosp Pharm 1979;36:7368.
  • 59
    Siegel H, Kelley K, Stertz B, et al. The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res 1999;34:917.
  • 60
    Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A., The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999;40:11416.
  • 61
    Veggiotti P, Cieuta C, Rey E, Dulac O., Lamotrigine in infantile spasms. Lancet 1994;344:13756.
  • 62
    Armijo JA, Arteaga R, Valdizan EM, Herranz JL, Coadministration of vigabatrin and valproate in children with refractory epilepsy. Clin Neuropharmacol 1992;6:45969.
  • 63
    Stolarek I, Blacklaw J, Forrest G, Brodie MJ, Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry 1994;57:9214.
  • 64
    Schapel GJ, Black AB, Lam EL, Robinson M, Dollman WB, Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure 1996;5:516.
  • 65
    Kugler SL, Sachdeo RC, Wenger EC, Maradani S, Kumar D, Mandelbaum DE, Efficacy of combination topiramate and lamotrigine in refractory epilepsy in children. Epilepsia 1997;38(Suppl. 8):1923.
  • 66
    Leach JP, Brodie MJ, Synergism with GABAergic drugs in refractory epilepsy. Lancet 1994;343:1650.
  • 67
    Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP, Lamotrigine as add-on drug in typical absence seizures. Acta Neurol Scand 1995;91:2002.
  • 68
    Ferrie CD, Panayiotopoulos CP, Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure 1994;3:1579.
  • 69
    Reife R., Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs. In: FrenchJ, LeppikI, DichterMA, eds. Antiepileptic drug development. Advances in Neurology, v. 76. Philadelphia : Lippincott-Raven, 1998:95103.
  • 70
    Czuczwar SJ, Borowicz KK, Kleinrok Z, Tutka P, Zarnowski T, Turski WA, Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice. Eur J Pharmacol 1995;281:32733.
  • 71
    Czuczwar SJ, Experimental background for synergistic and additive effects of antiepileptic drugs. Epileptologia 1998;6(Suppl. 2):219.
  • 72
    Löscher W, Rundfeldt C, Honack D., Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur J Neurosci 1993;5:154550.
  • 73
    Van Rijn CM, Willems E, Rodrigues de Miranda JF, Zwart JPC, Dirksen RA, Molecular model for the synergic interaction between GABA and general anesthetics. Eur J Pharmacol 1999;371:21326.
  • 74
    Löscher W, Ebert U., Basic mechanisms of seizure propagation: targets for rational drug design and rational polypharmacy. In: HomanRW, LeppikIE, LothmanEW, PenryJK, TheodoreWH, eds. Rational polypharmacy. Amsterdam : Elsevier Science BV, 1996:1743.
  • 75
    Czuczwar SJ, Turski L, Chmielewska B, Turski WA, Kleinrok Z., Modification of the anticonvulsant activity of 2-amino-5-phosphonovalerate by agents affecting different neurotransmitter systems. Neuropharmacology 1985;24:9658.
  • 76
    Borowicz KK, Luszczki J, Szadkowski M, Kleinrok Z, Czuczwar SJ, Influence of LY 300164, an antagonist of AMPA/kainate receptors, on the anticonvulsant activity of clonazepam. Eur J Pharmacol 1999;380:6772.
  • 77
    Rodger C, Pleuvry BJ, Protective effect of flunarizine and nifedipine alone and in combination with anticonvulsant drugs against PTZ-induced seizures in mice. Neuropharmacology 1993;32:25763.
  • 78
    DeLorey TM, Kissin I, Brown P, Brown GB, Barbiturate-benzodiazepine interactions at the gamma-aminobutyric acid A receptor in rat cerebral cortical synaptoneurosomes. Anesth Analg 1993;77:598605.
  • 79
    Hoffman A, Habib G., Valproic acid intensifies the depressant action of phenobarbital and ethanol by a pharmacodynamic mechanism. J Pharm Sci 1994;83:7335.
  • 80
    Lothman EW, Basic mechanisms of seizure expression. In: HomanRW, LeppikIE, LothmanEW, PenryJK, TheodoreWH, eds. Rational polypharmacy. Amsterdam : Elsevier Science BV, 1996:916.
  • 81
    Löscher W., New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 1998;342:113.
  • 82
    Deckers CLP, Hekster YA, Keyser A, Meinardi H, Renier WO, Drug load in clinical trials: a neglected factor. Clin Pharmacol Ther 1997;62:5925.